Study details
Enrolling now
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
NCT IDNCT06673017ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
26
Study length
about 3.2 years
Ages
18+
Locations
6 sites in CA, MI, NY +2
What this study is about
Researchers are testing PTM-101, a medication, when combined with neoadjuvant chemotherapy for people with borderline resectable or locally advanced pancreatic ductal adenocarcinoma. The trial will last about 1 year and aims to enroll approximately 26 adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take PTM-101
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology